Table 3.
Summary of prespecified adverse events recorded in the ICU
| Data (N = 82 patients) | |
|---|---|
| Neutropeniaa <1500/mm3 | 9 (11) |
| Delay between cyclophosphamide administration and neutropeniaa <500/mm3, days | 16 (2–25) |
| Number of patients with infection | 25 (30) |
| Location | |
| Urinary tract | 2 (8) |
| Lung | 15 (60) |
| Bacteremia | 4 (16) |
| Others | 4 (16) |
| Bacterial source | |
| Gram-positive | 3 (12) |
| Gram-negative | 16 (64) |
| Otherb | 1 (4) |
| No pathogen identified | 5 (20) |
| Delay between ICU admission and first infection event, days | 13.0 (4.5–19.75) |
| Number of patients with septic shock | 13 (16) |
| Number of patients presenting with hemorrhagic syndrome | 57 (69) |
| Number of packed red blood cells infused during ICU stay | 4.0 (0–7.5) |
| Delay between ICU admission and first hemorrhagic event, days | 1.0 (0–5.0) |
| Cause of death in ICU | |
| Infection | 4 (31) |
| Disease flare | 9 (69) |
ICU intensive care unit
Data are presented as number (%) or median (interquartile range)
aMissing data: 2
bVirus